← All Cartesian Therapeutics, INC filings

Cartesian Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RNAC
Cartesian Therapeutics, INC
10-K: Cartesian Therapeutics Reports 2024 Results, Highlights Progress in mRNA Cell Therapy for Autoimmune Diseases
Cartesian Therapeutics' 2024 10-K filing details the company's focus on mRNA cell therapy for autoimmune diseases, highlighting clinical trial results and future plans.
NASDAQ
RNAC
Cartesian Therapeutics, INC
10-K: Cartesian Therapeutics Outlines Registered Securities and Capital Structure in 10-K Filing
Cartesian Therapeutics details its registered securities, including common stock and contingent value rights, along with its capital structure, in its latest 10-K filing.